Middle East Journal of Cancer

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

News

Forms

Journal Metrics

Incidence of Bladder Cancer at a Tertiary Care Centre in North Karnataka

Document Type : Original Article(s)

Authors

1 Department of Biotechnology and Microbiology, Karnatak University Dharwad, Karnataka, India

2 Department of Zoology, KLES B. K. Arts, Science and Commerce College, Chikodi, Karnataka, India

3 Urinary Biomarkers Research Centre, Department of Urology, KLES Dr. Prabhakar Kore Hospital and Medical Research Centre, Belagavi-590010, Karnataka, India

4 Department of Biotechnology, KAHER’s Dr. Prabhakar Kore Basic and Applied Science Research Center, V. K. Institute of Dental Sciences Campus, Karnataka, India

Abstract

Background: Understanding the prevalence, clinical characteristics, and changing demographics of Indian bladder cancer (BC) has emerged as an important field of study. Herein, we aimed to present the case series of BC patients of a single tertiary care centre in North Karnataka.
Method: This retrospective study was designed for 14 years from 2004 to 2017, conducted in the urology clinic. A total of 468 newly diagnosed BC patients (male = 415; female = 53) were included in the study. Sociodemographic, clinical characteristics, cystoscopic, and pathological findings were recorded and analyzed via IBM SPSS statistics software Inc. version 20.0.
Results: The mean age of the patients was male = 62.27 years and female = 54.22 years. Hematuria was a common clinical symptom in both genders accounting for 42.02 versus 45.28% of the male and female subjects, respectively. Transition cell carcinoma (TCC) was the common variant seen in the male and female participants (92.99 versus 94.88%, respectively). Low-grade cancer was found in patients with >60 years of age in 39.7% versus 42.1% of respectively the males and females (P = 0.002) as compared to the patients <60 years. Non-muscle invasive BC in the males and females was respectively 55.42% versus 52.83%, whereas muscle-invasive cancer was 44.57% versus 47.16% respectively in the two groups (P = 0.008). 53 patients (29.22%) in the both genders received transurethral resection/intravesical Bacilli Calmette-Guerin therapy, which showed a significant improvement (P = 0.019).
Conclusion: Transition cell carcinoma was found to remain the predominant type of BC with painless hematuria in North Karnataka population. This has seriously affected the public health; this trend is expected to be continued due to the high prevalence of smoking. There should be further emphasis on primary prevention of BC by conducting smoking cessation awareness programs.

Keywords

Full Text

How to cite this article:

Puranik SI, Ghagane SC, Nerli RB, Hiremath MB. Incidence of bladder cancer at a tertiary care centre in north Karnataka. Middle East J Cancer. 2022;13(2):363-71. doi: 10. 30476/mejc.2021.86866.1374.

References
  1. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234-41. doi: 10.1016/j.eururo.2012.07.033.
  2. Singh JP, Priyadarshi V, Pal DK. A clinicoepidemiological study of young age bladder tumors: An eastern Indian scenario. J Cancer Res Ther. 2016;12(2):751-4. doi: 10.4103/0973-1482.154028.
  3. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56(3):430-42. doi: 10.1016/j.eururo.2009.06.028.
  4. Gupta P, Jain M, Kapoor R, Muruganandham K, Srivastava A, Mandhani A. Impact of age and gender on the clinicopathological characteristics of bladder cancer. Indian J Urol. 2009;25(2):207-10. doi:10.4103/0970-1591.52916.
  5. Balaji V, Seshiah V, Ashtalakshmi G, Ramanan SG, Janarthinakani M. A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population. Indian J Endocrinol Metab. 2014;18(3):425-7. doi:10.4103/2230-8210.
  6. Ghagane S, Nerli R, Hiremath M, Wagh A, Magdum P. Incidence of prostate cancer at a single tertiary care center in North Karnataka. Indian J Cancer. 2016;53:429-31. doi: 10.4103/0019-509X.200671.
  7. Yuvaraja TB, Waigankar S, Bakshi G, Prakash G. Genitourinary cancers: Summary of Indian data. South Asian J Cancer. 2016;5(3):122-4. doi:10.4103/2278-330X.187577.
  8. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306(7):737-45. doi:10.1001/jama.2011.1142.
  9. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234-41. doi: 10.1016/j.eururo.2012.07.033.
  10. Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al. EAU guidelines on muscleinvasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778-92.doi: 10.1016/j.eururo.2013.11.046.
  11. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017; 71(1):96-108. doi: 10.1016/j.eururo.2016.06.010.
  12. Srivastava P, Kapoor R, Mittal RD. Association of single nucleotide polymorphisms in promoter of matrix metalloproteinase-2, 8 genes with bladder cancer risk in Northern India. Urol Oncol. 2013;31(2):247-54.doi: 10.1016/j.urolonc.2011.01.001.
  13. Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol. 2011;186(6):2158-67. doi: 10.1016/j.juro.2011.07.076.
  14. Alfred Witjes J, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71(3):462-75. doi: 10.1016/j.eururo.2016.06.020.
  15. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152-65. doi:10.1016/j.ccr.2014.01.009.
  16. Royce TJ, Feldman AS, Mossanen M, Yang JC, Shipley WU, Pandharipande PV, et al. Comparative effectiveness of bladder-preserving tri-modality therapy versus radical cystectomy for muscle-invasive bladder cancer. Clin Genitourin Cancer. 2019;17(1):23-31. e3. doi: 10.1016/j.clgc.2018.09.023.
  17. Babjuk M. Trends in bladder cancer incidence and mortality: Success or disappointment? Eur Urol. 2017;71(1):109-10. doi: 10.1016/j.eururo.2016.06.040.
  18. Lerner SP, Dinney C, Kamat A, Bivalacqua TJ, Nielsen M, O'Donnell M, et al. Clarification of bladder cancer disease states following treatment of patients with intravesical BCG. Bladder Cancer. 2015;1(1):29-30. doi: 10.3233/BLC-159002.
  19. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5): E359-86. doi: 10.1002/ijc.29210.
  20. Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15(1):25-41. doi:10.1038/nrc3817.
  21. Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, et al. Bladder cancer. Nat Rev Dis Primers. 2017; 3:17022. doi: 10.1038/nrdp.2017.22.
  22. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017; 171(3):540-56. doi: 10.1016/j.cell.2017.09.007.
  23. Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. 2017;72(4):544-54. doi:10.1016/j.eururo.2017.03.030.
  24. Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemiology of bladder cancer. Hematology/Oncology Clinics of North America. 1992;6(1):1-30.doi:10.1016/S0889-8588(18)30360-5.
  25. Nerli RB, Reddy M, Koura AC, Prabha V, Ravish IR, Amarkhed S. Cystoscopy-assisted laparoscopic partial cystectomy. J Endourol. 2008;22(1):83-6. doi:10.1089/end.2007.0105.
  26. Colmers IN, Majumdar SR, Yasui Y, Bowker SL, Marra CA, Johnson JA. Detection bias and overestimation of bladder cancer risk in type 2 diabetes: a matched cohort study. Diabetes Care. 2013;36(10):30705.doi:10.2337/dc130.
Middle East Journal of Cancer
Volume 13, Issue 2 - Serial Number 50
April 2022
Pages 363-371
Files
Share
How to cite
Statistics